Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 16/20 | 0.42 |
| ▸ | NFKB2 | Q00653 | 16/20 | 0.42 |
| ▸ | RELA | Q04206 | 16/20 | 0.42 |
| ▸ | TOP2A | P11388 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3291408 | 0.77 | TOP2A (0.37) | TOP2A | |
| SCHEMBL3293061 | 0.77 | TOP2A (0.37) | TOP2A | |
| SCHEMBL4230474 | 0.76 | PRKAB2 (0.41) | TOP2ACYP19A1KDM4EALDH1A1HPGD | |
| SCHEMBL3290570 | 0.74 | NFKB1 (0.48) | NFKB1NFKB2RELACYP19A1 | |
| SCHEMBL3295022 | 0.74 | NFKB1 (0.48) | NFKB1NFKB2RELACYP19A1KDM4E | |
| SCHEMBL30068254 | 0.73 | TOP2A (0.32) | TOP2A | |
| SCHEMBL3294579 | 0.71 | NFKB1 (0.42) | NFKB1NFKB2RELAALDH1A1 | |
| SCHEMBL6081871 | 0.71 | NFKB1 (0.36) | NFKB1NFKB2RELATOP2AKDM4E | |
| SCHEMBL20211424 | 0.70 | TOP2A (0.45) | TOP2A | |
| SCHEMBL23533600 | 0.67 | GLS (0.39) | TOP2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728155-B2 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH LLC (US) | 2010-06-01 | — | — | US | disclosed |
| EP-1675842-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wyeth (US) | 2006-07-05 | — | — | EP | disclosed |
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | WYETH (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005040146-A1 | DIHYDROBENZOFURANYL ALKANAMINES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WYETH (US) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124692-A1 | Dihydrobenzofuranyl alkanamines and methods for using same as cns agents | HTR2C, HTR1A, HTR1B | NFKB1 3154/4885NFKB2 3050/4885RELA 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.